WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 522378
Description: SCH-50911 is a selective GABAB antagonist developed by Schering-Plough Corporation. Its main applications are in pharmacology research. SCH-50911 also acts as an anticonvulsant under normal conditions, and so counteracts both the depressant and pro-convulsant effects of GHB overdose. This pharmacological profile makes SCH-50911 a promising candidate as a GHB antidote for human use, and might also make it useful for treating overdoses of other GABAB agonists such as Baclofen.
MedKoo Cat#: 522378
Chemical Formula: C8H15NO3
Exact Mass: 173.10519
Molecular Weight: 173.21
Elemental Analysis: C, 55.47; H, 8.73; N, 8.09; O, 27.71
Synonym: SCH-50911; SCH 50911; SCH50911.
IUPAC/Chemical Name: (S)-2-(5,5-dimethylmorpholin-2-yl)acetic acid
SMILES Code: CC1(CO[C@H](CN1)CC(O)=O)C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 173.21 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: van Nieuwenhuijzen PS, McGregor IS, Chebib M, Hunt GE. Regional Fos-expression induced by γ-hydroxybutyrate (GHB): comparison with γ-butyrolactone (GBL) and effects of co-administration of the GABAB antagonist SCH 50911 and putative GHB antagonist NCS-382. Neuroscience. 2014 Sep 26;277:700-15. doi: 10.1016/j.neuroscience.2014.07.056. Epub 2014 Aug 1. PubMed PMID: 25088910.
2: Carai MA, Colombo G, Gessa GL. Protection by the GABAB receptor antagonist, SCH 50911, of gamma-hydroxybutyric acid-induced mortality in mice. Eur J Pharmacol. 2004 Oct 25;503(1-3):77-80. PubMed PMID: 15496299.
3: Carai MA, Brunetti G, Lobina C, Serra S, Vacca G, Minardi G, Colombo G, Gessa GL. Proconvulsive effect of the GABA(B) receptor antagonist, SCH 50911, in rats undergoing ethanol withdrawal syndrome. Eur J Pharmacol. 2002 Jun 12;445(3):195-9. PubMed PMID: 12079684.
4: Erhardt S, Nissbrandt H, Engberg G. Activation of nigral dopamine neurons by the selective GABA(B)-receptor antagonist SCH 50911. J Neural Transm. 1999;106(5-6):383-94. PubMed PMID: 10443545.
5: Ong J, Marino V, Parker DA, Kerr DI, Blythin DJ. The morpholino-acetic acid analogue Sch 50911 is a selective GABA(B) receptor antagonist in rat neocortical slices. Eur J Pharmacol. 1998 Nov 27;362(1):35-41. PubMed PMID: 9865527.
6: Hosford DA, Wang Y, Liu CC, Snead OC 3rd. Characterization of the antiabsence effects of SCH 50911, a GABA-B receptor antagonist, in the lethargic mouse, gamma-hydroxybutyrate, and pentylenetetrazole models. J Pharmacol Exp Ther. 1995 Sep;274(3):1399-403. PubMed PMID: 7562514.
7: Bolser DC, Blythin DJ, Chapman RW, Egan RW, Hey JA, Rizzo C, Kuo SC, Kreutner W. The pharmacology of SCH 50911: a novel, orally-active GABA-beta receptor antagonist. J Pharmacol Exp Ther. 1995 Sep;274(3):1393-8. PubMed PMID: 7562513.
SCH-50911 is likely to be a useful antidote for GHB overdose in non-addicted individuals, its use in people who are dependent on GHB or its analogues could be potentially dangerous as it might precipitate acute withdrawal symptoms, and additional anticonvulsants such as diazepam would most likely be required to counteract the risk of life-threatening seizures.